Relapsing Multiple Sclerosis: Clinical Trials

7 trials for Relapsing Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 32Completed 2
Phase 11Completed 1

Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
CNM-Au8 - Relapsing Multiple Sclerosis
Phase 2 / Phase 3CompletedClene Nanomedicine552020-10-222023-12-08
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
Tolebrutinib - Relapsing Multiple Sclerosis
Phase 2CompletedSanofi1252019-09-232025-10-23
Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) - Relapsing Multiple Sclerosis
Phase 2CompletedSanofi1302019-03-292025-09-17
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
Ofatumumab, Matching placebo of ofatumumab - Relapsing Multiple Sclerosis
Phase 2CompletedNovartis Pharmaceuticals642018-03-152022-04-29
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Ozanimod, Placebo - Relapsing Multiple Sclerosis
Phase 2 / Phase 3CompletedCelgene2582012-09-182021-02-11
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
Trichuris suis ova - Relapsing Multiple Sclerosis
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet102010-05-012011-11-10
CDP323 Biomarker Study
CDP323, Placebo - Relapsing Multiple Sclerosis
Phase 1 / Phase 2CompletedUCB Pharma712008-07-012011-09-12

Narrower conditions

Multiple Sclerosis (2)  ·  Demyelinating Diseases (1)  ·  Optic Nerve Diseases (1)  ·  Optic Neuritis (1)

Broader conditions

Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Demyelinating Autoimmune Diseases, CNS (2)  ·  Immune System Diseases (2)  ·  Nervous System Diseases (2)  ·  Cranial Nerve Diseases (1)  ·  Demyelinating Diseases (1)  ·  Eye Diseases (1)

Interventions

CDP323 (1)  ·  ofatumumab (1)  ·  ozanimod (1)

Sponsors

Sanofi (2)  ·  Celgene (1)  ·  Clene Nanomedicine (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Novartis Pharmaceuticals (1)  ·  UCB Pharma (1)

Countries

Russia (4)  ·  Spain (3)  ·  Ukraine (3)  ·  United States (3)  ·  Canada (2)  ·  Czechia (2)  ·  Estonia (2)  ·  France (2)  ·  Netherlands (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Denmark (1)  ·  Georgia (1)  ·  Greece (1)

Results publications

PMID 23472197, PMID 25698173, PMID 26879276, PMID 30043658, PMID 34418400

NIH funding

2018 (2)